Sorry, this activity has expired and is no longer available for CME credit. You may still enjoy the program.
CME Information
Provider Statement: This continuing medical education activity is provided by 
.
Support Statement: This activity is supported by an educational grant from Amgen, Inc.
Target Audience: The intended audience for the activity is family practice physicians and other health care professionals involved in the treatment of patients with dyslipidemia.
Learning Objectives: Upon successful completion of this activity, participants should be better able to:
- Examine the latest clinical evidence regarding the impact of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors on cardiovascular outcomes both in patients with and without diabetes.
- Review the safety and efficacy of very low LDL-C levels and implications for patient cardiovascular health.
- Utilize PCSK9 inhibitors in accordance with the latest clinical evidence and guidelines.
- Implement strategies to overcome barriers that impede the use of PCSK9 inhibitors.
Activity Chair:
Peter P. Toth, MD, PhD, FAAFP, FICA, FAHA, FNLA, FASPC, FCCP, FACC
Director, Preventative Cardiology
CGH Medical Center
Sterling, IL
Professor, Clinical Family & Community Medicine
University of Illinois College of Medicine
Peoria, IL
Professor of Clinical Medicine
Michigan State University College of Osteopathic Medicine
East Lansing, MI
Adjunct Associate Professor Medicine
Johns Hopkins University School of Medicine
Baltimore, MD
Faculty:
Michael Miller, MD, FACC, FAHA
Professor of Cardiovascular Medicine, Epidemiology, and Public Health
University of Maryland School of Medicine
Director, Center for Preventive Cardiology
University of Maryland Medical Center
Cardiology Division
Baltimore, MD
James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA
Lipidology & Cardiovascular Disease Prevention
Clinical Assistant Professor of Medicine
NYU Medical School & NYU Center for CV Prevention
Director, Bellevue Hospital Lipid Clinic
New York, NY
Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Accreditation:
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation:
Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This Enduring Material activity, Rapid Fire Roundtable: Addressing Clinical Challenges Regarding the Use of PCSK9 Inhibitors, has been reviewed and is acceptable for up to 0.75 Prescribed credit(s) by the American Academy of Family Physicians. AAFP certification begins 01/14/2019. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AMA/AAFP Equivalency: AAFP Prescribed Credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 Credit(s)™ toward the AMA Physician’s Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed, not as Category 1.
This enduring material is approved for 1 year from the date of original release, January 14, 2019 to January 13, 2020.
How to Participate in This Activity and Obtain CME Credit:
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue Prescribed Credits and AMA PRA Category 1 Credit(s)™ Certificate.
Disclosures:
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.
The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.
Activity Chair and Faculty report the following relationships:
Peter P. Toth, MD, PhD
Consulting Fee: Amarin, Amgen, AstraZeneca, Kowa, Merck, Novo Nordisk, Regeneron, Sanofi
Speakers Bureau: Amarin, Amgen, AstraZeneca, Kowa, Merck, Novo Nordisk, Regeneron, Sanofi
Michael Miller MD, FACC, FAHA
No relevant financial relationships to disclose.
James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA
Consulting Fee: Amarin, Amgen
Speakers Bureau: Aegerion, Akcea, Alexion, Amarin, Amgen, Kastle, Regeneron, Sanofi
Contracted Research: Aegerion, Pfizer
Advisory Boards: Aegerion, Akcea, Amgen, Kastle, Regeneron, Sanofi
Reviewer reports the following relationship(s):
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationship to disclose.
Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage:
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.
Copyright Statement:
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at cme@vindicoCME.com